The Experts below are selected from a list of 39 Experts worldwide ranked by ideXlab platform
Kjell Fuxe - One of the best experts on this subject based on the ideXlab platform.
-
on the role of p2x 7 receptors in dopamine Nerve Cell Degeneration in a rat model of parkinson s disease studies with the p2x 7 receptor antagonist a 438079
Journal of Neural Transmission, 2010Co-Authors: Daniel Marcellino, Diana Suarezboomgaard, Maria Dolores Sanchezreina, Jose A Aguirre, Takashi Yoshitake, Shimako Yoshitake, Beth Hagman, Jan Kehr, Luigi F Agnati, Kjell FuxeAbstract:The role of the ATP-gated receptor, P2X7, has been evaluated in the unilateral 6-OHDA rat model of Parkinson’s disease using the P2X7 competitive antagonist A-438079. Nigral P2X7 immunoreactivity was mainly located in microglia but also in astroglia. A-438079 partially but significantly prevented the 6-OHDA-induced depletion of striatal DA stores. However, this was not associated with a reduction of DA Cell loss. Blockade of P2X7 receptors may represent a novel protective strategy for striatal DA terminals in Parkinson’s disease and warrants further future investigation.
Andre Delacourte - One of the best experts on this subject based on the ideXlab platform.
-
comparative biochemistry of tau in progressive supranuclear palsy corticobasal Degeneration ftdp 17 and pick s disease
Brain Pathology, 1999Co-Authors: Luc Buee, Andre DelacourteAbstract:Neurodegenerative disorders referred to as tauopathies have Cellular hyperphosphorylated tau protein aggregates in the absence of amyloid deposits. Comparative biochemistry of tau aggregates shows that they differ in both phosphorylation and content of tau isoforms. The six tau isoforms found in human brain contain either three (3R) or four microtubule-binding domains (4R). In Alzheimer's disease, all six tau isoforms are abnormally phosphorylated and aggregate into paired helical filaments. They are detected by immunoblotting as a major tau triplet (tau55, 64 and 69). In corticobasal Degeneration and progressive supranuclear palsy, only 4R-t.au isoforms aggregate into twisted and straight filaments respectively. They appear as a major tau doublet (tau64 and 69). Finally, in Pick's disease, only 3R-tau isoforms aggregate into random coiled filaments. They are characterized by another major tau doublet (tau55 and 64). These differences in tau isoforms may be related to either the Degeneration of particular Cell populations in a given disorder or aberrant Cell trafficking of particular tau isoforms. Finally, recent findings provide a direct link between a genetic defect in tau and its abnormal aggregation into filaments in fronto-temporal dementia with Parkinsonism linked to chromosome 17, demonstrating that tau aggregation is sufficient for Nerve Cell Degeneration. Thus, tau mutations and polymorphisms may also be instrumental in many neurodegenerative disorders.
Daniel Marcellino - One of the best experts on this subject based on the ideXlab platform.
-
on the role of p2x 7 receptors in dopamine Nerve Cell Degeneration in a rat model of parkinson s disease studies with the p2x 7 receptor antagonist a 438079
Journal of Neural Transmission, 2010Co-Authors: Daniel Marcellino, Diana Suarezboomgaard, Maria Dolores Sanchezreina, Jose A Aguirre, Takashi Yoshitake, Shimako Yoshitake, Beth Hagman, Jan Kehr, Luigi F Agnati, Kjell FuxeAbstract:The role of the ATP-gated receptor, P2X7, has been evaluated in the unilateral 6-OHDA rat model of Parkinson’s disease using the P2X7 competitive antagonist A-438079. Nigral P2X7 immunoreactivity was mainly located in microglia but also in astroglia. A-438079 partially but significantly prevented the 6-OHDA-induced depletion of striatal DA stores. However, this was not associated with a reduction of DA Cell loss. Blockade of P2X7 receptors may represent a novel protective strategy for striatal DA terminals in Parkinson’s disease and warrants further future investigation.
Jan Kehr - One of the best experts on this subject based on the ideXlab platform.
-
on the role of p2x 7 receptors in dopamine Nerve Cell Degeneration in a rat model of parkinson s disease studies with the p2x 7 receptor antagonist a 438079
Journal of Neural Transmission, 2010Co-Authors: Daniel Marcellino, Diana Suarezboomgaard, Maria Dolores Sanchezreina, Jose A Aguirre, Takashi Yoshitake, Shimako Yoshitake, Beth Hagman, Jan Kehr, Luigi F Agnati, Kjell FuxeAbstract:The role of the ATP-gated receptor, P2X7, has been evaluated in the unilateral 6-OHDA rat model of Parkinson’s disease using the P2X7 competitive antagonist A-438079. Nigral P2X7 immunoreactivity was mainly located in microglia but also in astroglia. A-438079 partially but significantly prevented the 6-OHDA-induced depletion of striatal DA stores. However, this was not associated with a reduction of DA Cell loss. Blockade of P2X7 receptors may represent a novel protective strategy for striatal DA terminals in Parkinson’s disease and warrants further future investigation.
Beth Hagman - One of the best experts on this subject based on the ideXlab platform.
-
on the role of p2x 7 receptors in dopamine Nerve Cell Degeneration in a rat model of parkinson s disease studies with the p2x 7 receptor antagonist a 438079
Journal of Neural Transmission, 2010Co-Authors: Daniel Marcellino, Diana Suarezboomgaard, Maria Dolores Sanchezreina, Jose A Aguirre, Takashi Yoshitake, Shimako Yoshitake, Beth Hagman, Jan Kehr, Luigi F Agnati, Kjell FuxeAbstract:The role of the ATP-gated receptor, P2X7, has been evaluated in the unilateral 6-OHDA rat model of Parkinson’s disease using the P2X7 competitive antagonist A-438079. Nigral P2X7 immunoreactivity was mainly located in microglia but also in astroglia. A-438079 partially but significantly prevented the 6-OHDA-induced depletion of striatal DA stores. However, this was not associated with a reduction of DA Cell loss. Blockade of P2X7 receptors may represent a novel protective strategy for striatal DA terminals in Parkinson’s disease and warrants further future investigation.
